Head-to-head · WeighScore
telos rx vs Vytora Health
The verdict
telos rx takes it — 85.4/100 to 72.3/100.
telos rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified, HIPAA telehealth with one of the deepest published catalogs on the board — compounded semaglutide and tirzepatide (oral and microdosed routes included) alongside PT-141, intranasal NAD+, and a long recovery/GH peptide bench — with compounded GLP-1 starting from $49/mo on an annual plan.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | telos rx | Vytora Health |
|---|---|---|
| WeighScore | 85.4/100 | 72.3/100 |
| Grade | B | C |
| Scorecard rank | #9 | #79 |
| Semaglutide | From $49/mo (annual) | $180/mo (all doses, compounded) |
| Tirzepatide | $99/mo (annual) | $249/mo (all doses, compounded) |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #9 · B
Strengths
- Deep published catalog — sema, tirz, PT-141, intranasal NAD+, recovery/GH peptides, GHK-Cu, Dihexa, HRT
- Needle-free and oral GLP-1 options, not injection-only
- LegitScript-certified and HIPAA, with US providers and pharmacies, HSA/FSA and free shipping
- Low GLP-1 entry — from $49/mo microdosed on an annual plan
Where it loses points
- Everything is compounded and not FDA-approved, including the peptides
- Pricing is opaque outside GLP-1 and the lowest rates require annual lock-in
- No named clinicians and thin third-party reviews
- Several research-grade peptides carry limited clinical evidence
Graded #79 · C
Strengths
- All 50 states plus DC, with per-state video-vs-audio compliance disclosed
- Both compounded and brand-name options on one platform — uncommon
- LegitScript Approved and HIPAA compliant
- Pharmacy partners named publicly: Vials Pharmacy (TX) and Greenwich Biosciences
- Operating entity disclosed: Wasef Health, PC (Pinellas Park, FL)
Where it loses points
- Brand-name Mounjaro/Zepbound at $1,399/mo is near retail — insured patients may do better via LillyDirect Self Pay ($449-$699/mo)
- Compounded tirzepatide at $249/mo is mid-market, above the $149-199 floor
- Dose tiers aren't broken out — 'all doses included' means low-dose patients pay the same as high-dose
- Initial consultation cost not shown on the public pricing page
- Limited per-prescriber state licensure detail
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.